MedPath

Study of Rubella Immunity. Response to Vaccination of Subjects With Very Low, Equivocal or Undetectable Titers of Rubella Virus Antibodies

Not Applicable
Completed
Conditions
Pregnancy
Interventions
Biological: Determination of Anti-Rubella Antibody, E1
Registration Number
NCT02934295
Lead Sponsor
Hopital Foch
Brief Summary

The aim of the research is to study humoral and cellular immunity in pregnant women for who the level of rubella virus antibodies is weakly positive, equivocal or negative with the usual laboratory technique.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
192
Inclusion Criteria
  • Women over 18
  • Rubella serology negative, ambiguous or weakly positive during a first prenatal consultation and for which the second determination of the immunity anti rubella is necessary after 18 weeks of pregnancy
  • Accepting the rubella vaccination after the childbirth;
  • Accepting a blood test, during a postnatal consultation, 6 in 8 weeks after vaccination, to verify their immunity towards the virus of the rubella.
  • Affiliated to a social security scheme
  • Having given a written consent
Read More
Exclusion Criteria
  • Rubella contracted since the first serology realized during the first prenatal consultation
  • Autoimmune pathologies
  • Intolerance / allergy known about a previous vaccination whatever it is
  • Immunosuppression (HIV, transplants)
  • Injection of multivalent immunoglobulins (except anti-D)
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Pregnant womenDetermination of Anti-Rubella Antibody, E1-
Primary Outcome Measures
NameTimeMethod
Level of Anti-Rubella Antibody, E18 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Hôpital Foch

🇫🇷

Suresnes, France

Hôpital Antoine-Béclère

🇫🇷

Clamart, France

© Copyright 2025. All Rights Reserved by MedPath